{
    "clinical_study": {
        "@rank": "159586", 
        "acronym": "GLANCE", 
        "arm_group": [
            {
                "arm_group_label": "Glucosamine and Chondroitin", 
                "arm_group_type": "Experimental", 
                "description": "Glucosamine and Chondroitin"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Inactive ingredients"
            }
        ], 
        "brief_summary": {
            "textblock": "A common starting dose of glucosamine and chondroitin will reduce inflammation as reflected\n      by a reduction in serum C-reactive protein."
        }, 
        "brief_title": "Glucosamine and Chondroitin Effects", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Inflammation", 
        "condition_browse": {
            "mesh_term": "Inflammation"
        }, 
        "detailed_description": {
            "textblock": "Use of glucosamine and chondroitin have been associated with reduced cancer and overall\n      mortality.  The aim of this study is to determine whether a common starting dose of\n      glucosamine and chondroitin (1500 mg/d + 1200 mg/d, respectively) reduces systemic\n      inflammation as reflected by a reduction in high sensitivity C-reactive protein."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy\n\n          -  Overweight (body mass index kg/m2 (BMI) between 25 and 32.5)\n\n          -  Non-smoking men and women\n\n          -  Aged 20-55y\n\n        Exclusion Criteria:\n\n          -  Chronic medical illness, history of gastrointestinal, hepatic, or renal disorders, or\n             inflammatory conditions (including autoimmune and inflammatory diseases)\n\n          -  Pregnancy or lactation\n\n          -  Currently on a weight-loss diet\n\n          -  BMI (body mass index) < 25 or > 30\n\n          -  Alcohol intake of greater than 2 drinks/day\n\n          -  Current use of prescription or over-the-counter medications, (Excluding oral\n             contraceptives and hormone-secreting IUDs), including use of aspirin or NSAIDs more\n             than 2 days per week\n\n          -  Abnormal renal, liver or metabolic test\n\n          -  Inability to swallow pills\n\n          -  Known allergy to shellfish\n\n          -  Not willing to take pills made from shellfish or animal sources\n\n          -  Intention to relocate out of study area within next 4 months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 4, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01682694", 
            "org_study_id": "7798"
        }, 
        "intervention": [
            {
                "arm_group_label": "Glucosamine and Chondroitin", 
                "description": "Glucosamine (1500 mg) and Chondroitin (1200 mg)", 
                "intervention_name": "Glucosamine and Chondroitin", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "Nutramax"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "placebo", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 23, 2014", 
        "link": {
            "url": "http://GLANCEstudy.INFO"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Seattle", 
                    "country": "United States", 
                    "state": "Washington", 
                    "zip": "98109"
                }, 
                "name": "Fred Hutchinson Cancer Research Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Glucosamine and Chondroitin Effects", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "hsCRP is a biomarker of systemic inflammation", 
            "measure": "hsCRP", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01682694"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The mechanisms of action of glucosamine and chondroitin are currently unknown.  Untargeted metabolomic assays of serum will be undertaken for exploratory analyses of potential effects of glucosamine and chondroitin.  Significant differences in abundance ratios of small molecules between the intervention and placebo will be reported.", 
            "measure": "untargeted (exploratory) serum metabolomics (differences in small molecule abundance ratios)", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "source": "Fred Hutchinson Cancer Research Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fred Hutchinson Cancer Research Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}